Free Newsletter
Eli Lilly's Alimta approval
The FDA has approved a third indication for Eli Lilly's cancer drug, Alimta. The agency approved Altima for use in combination with cisplatin to treat patients with non-small cell lung cancer and will be a first-line treatment for patients with locally advanced and metastatic lung cancer with nonsquamous histology. The drug received approval earlier for patients to receive in combination with cisplatin in cases of malignant pleural mesothelioma and alone for in patients with locally-advanced or metastatic non-small cell lung cancer who had already had already undergone chemotherapy. Eli Lilly release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: